in this issue
Regions :: North America :: U.S.
Merck Serono and Mersana to develop antibody-drug conjugates
7:44 AM MDT | June 24, 2014 | Deepti Ramesh
Merck KGaA says that its biopharmaceutical division, Merck Serono (Darmstadt, Germany), has signed an agreement with Mersana Therapeutics (Cambridge, MA) to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and delivers the cytotoxic drug to cancer cells, which could raise drug levels at the tumor site. Mersana and Merck Serono will leverage Mersana’s Fleximer technology to generate ADCs for multiple undisclosed targets, and the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee